GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Capex-to-Revenue

STTK (Shattuck Labs) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shattuck Labs's Capital Expenditure for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $3.00 Mil.

Hence, Shattuck Labs's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.00.


Shattuck Labs Capex-to-Revenue Historical Data

The historical data trend for Shattuck Labs's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Capex-to-Revenue Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial 0.05 0.07 0.26 17.81 0.25

Shattuck Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 - - -

Competitive Comparison of Shattuck Labs's Capex-to-Revenue

For the Biotechnology subindustry, Shattuck Labs's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shattuck Labs's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shattuck Labs's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shattuck Labs's Capex-to-Revenue falls into.



Shattuck Labs Capex-to-Revenue Calculation

Shattuck Labs's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.407) / 1.657
=0.25

Shattuck Labs's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 2.997
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shattuck Labs  (NAS:STTK) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Shattuck Labs Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shattuck Labs Business Description

Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Executives
Taylor Schreiber director, officer: Chief Executive Officer 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout officer: See Remarks C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill officer: See Remarks 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla officer: Chief Technical Officer 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein director 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson officer: General Counsel 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower director, 10 percent owner, officer: Chairman 3317 BOWMAN AVE, AUSTIN TX 78703
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite officer: Chief Medical Officer 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung officer: Chief Business Officer C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744